Matching-Adjusted Indirect Comparison of Daratumumab-Pomalidomide-Dexamethasone and Pomalidomide-Bortezomib-Dexamethasone in Relapsed/Refractory Multiple Myeloma
This analysis suggests that DPd improves PFS and might improve OS versus PVd in patients with RRMM. Additional evidence from head-to-head trials or real-world patient databases are warranted to confirm these results.
Authors
- Caitlin Daly (ORCID: https://orcid.org/0000-0002-8272-797X)
- David Bin‐Chia Wu (ORCID: https://orcid.org/0000-0002-0313-5758)
- Aaron Springford (ORCID: https://orcid.org/0000-0001-7179-9049)
- Wee Joo Chng (ORCID: https://orcid.org/0000-0003-2578-8335)
- Sung‐Hoon Jung (ORCID: https://orcid.org/0000-0003-3370-3987)
- Chengqing Wu (ORCID: https://orcid.org/0000-0002-7241-6123)
Institutions
- National University of Singapore (SG)
- Johnson & Johnson (Singapore) (SG)
- National University Cancer Institute, Singapore (SG)
- Chonnam National University Hwasun Hospital (KR)
- Cytel (United States) (US)
Publication Details
- Journal
- Clinical Lymphoma Myeloma & Leukemia
- Published
- 2025-02-15
- DOI
- https://doi.org/10.1016/j.clml.2025.02.007
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Johnson and Johnson